GENLISA Human SARS-CoV IgG ELISA |
|||
KBVH015-1 | Krishgen | 1 x 96 wells | EUR 302.5 |
Human IgG antibody Laboratories manufactures the test for sars-cov-1 antibody reagents distributed by Genprice. The Test For Sars-Cov-1 Antibody reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Test products are available in stock. Specificity: Test Category: For Group: Sars-Cov-1 Antibody
PLPro Antibody (SARS-CoV) |
||
BPS Bioscience | 250 µg | EUR 360 |
Description: Chicken polyclonal antibody recognizing the SARS-CoV Papain-like Protease (PLpro) as a 35 kDa protein. Purified from egg yolks. This antibody recognizes PLPro from both SARS-CoV-1 and SARS-CoV-2. Does not cross react with SARS-CoV 3CL protease. |
SARS-CoV Matrix Antibody |
||
ProSci | 0.02 mg | EUR 206.18 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
||
ProSci | 0.1 mg | EUR 523.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
||
ProSci | 0.02 mg | EUR 206.18 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
||
ProSci | 0.1 mg | EUR 523.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Envelope Antibody |
||
ProSci | 0.02 mg | EUR 206.18 |
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
SARS-CoV Envelope Antibody |
||
ProSci | 0.1 mg | EUR 523.7 |
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
Sars-Cov-1 Antibody information
SARS Antibody (CoV Spike) |
|||
GWB-7E7002 | GenWay Biotech | 0.1 mg | Ask for price |
Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) |
|||
IOV87952 | INVBIO | 20T/kit | EUR 46.8 |
Description: Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) is an in vitro diagnostic test for the qualitative detection of novel coronavirus antigens in human saliva, using the rapid immunochromatographic method. The identification is based on the monoclonal antibodies specific for the novel coronvirus antigen. It will provide information for clinical doctors to prescribe correct medications. |
SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] 100 ul |
|||
BSV-COV-AB-02 | BioServUK | 100 ul | EUR 602 |
Description: SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] (Spike (S2), Monoclonal) |
OAEF00177-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (SARS-CoV NP) Antibody |
|||
OAEF00177-1MG | Aviva Systems Biology | 1mg | EUR 471 |
OAEF00179-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (SARS-CoV NP) Antibody |
|||
OAEF00179-1MG | Aviva Systems Biology | 1mg | EUR 471 |
OAEF00193-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (SARS-CoV NP) Antibody |
|||
OAEF00193-1MG | Aviva Systems Biology | 1mg | EUR 471 |
OAEF00194-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (SARS-CoV NP) Antibody |
|||
OAEF00194-1MG | Aviva Systems Biology | 1mg | EUR 471 |
OAEF00195-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (SARS-CoV NP) Antibody |
|||
OAEF00195-1MG | Aviva Systems Biology | 1mg | EUR 471 |
SARS CoV-2 IgG Spike S1 (CoV-2 IgG S1) Antibody |
|||
abx137719-100tests | Abbexa | 100 tests | EUR 1237.5 |
SARS CoV-2 IgG Spike S1 (CoV-2 IgG S1) Antibody |
|||
abx137720-100tests | Abbexa | 100 tests | EUR 1237.5 |
SARS CoV-2 IgM Spike S1 (CoV-2 IgM S1) Antibody |
|||
abx137721-100tests | Abbexa | 100 tests | EUR 225 |
SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Test |
|||
ISIN-525H | Hangzhou AllTest Biotech | 25 Tests | EUR 18.75 |
OAEF00181-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (MERS & SARS-CoV NP) Antibody |
|||
OAEF00181-1MG | Aviva Systems Biology | 1mg | EUR 471 |
OAEF00183-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (MERS & SARS-CoV NP) Antibody |
|||
OAEF00183-1MG | Aviva Systems Biology | 1mg | EUR 471 |
OAEF00185-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (MERS & SARS-CoV NP) Antibody |
|||
OAEF00185-1MG | Aviva Systems Biology | 1mg | EUR 471 |
SARS CoV/SARS CoV 2 Spike Human mAb |
|||
E2S209908 | EnoGene | 100ul | EUR 595 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
SARS-CoV-2 (COVID-19) ORF8 Antibody |
|||
9287-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). SARS-CoV-2 virus proteins include structural proteins, non-structural proteins and accessory factors. The structure of SARS-CoV-2 consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. SARS-CoV-2 non-structural protein is ORF1ab that consists of 16 proteins (nsp1-nsp16), while accessory factors include ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF9c and ORF10. ORF8 may play a role in modulating host immune response (Probable). May play a role in blocking host IL17 cytokine by its interaction with host IL17RA (3). |